# A Clinical Study in Healthy Adults to See How the Body Processes and How Safe a Tablet That Combines Gemigliptin, Dapagliflozin, and Metformin is, Compared With Taking Zemiglo and Xigduo XR Together While Fasting.

> **NCT07399470** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **LG Chem** · enrollment: 58 (actual)

## Conditions studied

- Healthy Volunteers
- Fasting Conditions

## Interventions

- **DRUG:** Test drug: Fixed-dose combination of gemigliptin/dapagliflozin/metformin 50/10/1000 mg
- **DRUG:** Reference drug: Gemigliptin (Zemiglo) 50mg, Dapagliflozin/metformin (Xigduo XR) 10/1000 mg

## Key facts

- **NCT ID:** NCT07399470
- **Lead sponsor:** LG Chem
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2026-01-09
- **Primary completion:** 2026-02-28
- **Final completion:** 2026-02-28
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2026-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07399470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07399470, "A Clinical Study in Healthy Adults to See How the Body Processes and How Safe a Tablet That Combines Gemigliptin, Dapagliflozin, and Metformin is, Compared With Taking Zemiglo and Xigduo XR Together While Fasting.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07399470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*